Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Just to clarify: a nebuliser is the part of the device that changes the liquid medicine into a fine mist. The compressor, the base unit most people recognise, simply provides unidirectional air flow. So, you could use an Aerogen mesh nebuliser unit on a Philips compressor (or other if compatible). Therefore, if there are patients who already own a compressor it may be possible to simply issue the nebuliser with treatment. Compressors are relatively cheap though, usually less than £100 for at home units.
Aerogen produce a pro nebuliser that is autoclavable with hospital CSSD departments, therefore hospital based treatments may be a multi patient use. All at home nebulisers are single patient use and cleanable using basic detergents.
Fabulous line from RM in the NIHR article ‘ and we are also assessing the possibility of an exploratory trial in ventilated patients who persistently shed virus.’ So, not only are we aiming at possibly preventative dosing and treatment of moderate disease but they are also dipping their toe into the severe disease too. Very impressive.
Dr Fauci has emphasised the need for treatments to focus on this in early stages of Covid infection. States importance of routes of administration.
Title: Treatments for people with early COVID-19 infection is an urgent research focus.
Just a thought... is there any chance, ANY?! That conservatives will lock down England just in time to have a significant patient load for positive phase 3 trial data while reducing transmission rates and allowing those at lowest risk to continue their schooling. All to save Christmas? Nah, probably not....
This showed that those who had mild symptoms were more likely to loose antibodies more rapidly than those who had severe disease, most in approx 3 months. A vaccine is designed to initiate a similar mild response the the virus. This gives me even less confidence in a vaccine.
Next readout 15th December 2020 according to Stanford.
Stanford - race to a cure - immune modulator (cytokines) - interferon beta 1a
Sponsors: Synairgen Research Ltd., Cadila Healthcare Limited